An observational study in Pain and Nociceptive Pain, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by University of Wisconsin, Madison · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Nociceptive Pain with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Nociceptive Pain · United States.
Among the 16 studies in Nociceptive Pain with a site in United States, this one is one of 5 that started in 2024, is one of 4 observational ones, and was the 13th registered.
97 studies on the registry are indexed under Nociceptive Pain; 19 are open to participants now.
Browse Nociceptive Pain studies →2 of the 16 studies in Nociceptive Pain with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Nociceptive Pain studies recruiting now, 5 (42%) set no upper age limit and 4 (33%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 74 across 32 observational studies indexed under Nociceptive Pain.
Median enrollment 65 across the 12 interventional studies, 73 across the 4 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 16 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 1 study filed under Nociceptive Pain — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Nociceptive Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to determine if a PET/MRI scan using FDG can accurately identify the source of chronic pain. Identifying the source of pain may help doctors treat chronic pain more effectively. Approximately 128 participants will be enrolled and can expect to be on study for up to 12 months.
The investigators aim to precisely localize sites of increased inflammation and potentially pain generation and improve understanding of nociception and inflammation using a unique, hybrid PET/MRI approach in conjunction with intravenously, administered fluorodeoxyglucose (FDG), which has been shown with PET imaging to be an sensitive surrogate marker of inflammation.
The Primary Objective of this pilot prospective, observational research is to determine whether this approach, which combines PET/MRI and an FDA-approved radiotracer, 18F-Fluorodeoxyglucose (FDG), can accurately localize the sites of painful inflammation in individuals with persistent pain.
Secondary Objectives:
97 studies on the registry are indexed under Nociceptive Pain; 19 are open to participants now.
This study's planned enrollment of 128 is above the median of 74 across 32 observational studies indexed under Nociceptive Pain.
Browse Nociceptive Pain studies →University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
Compared within Nociceptive Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Participants with persistent post-surgical pain and asymptomatic individuals who have undergone joint arthroplasty (hip or knee) or joint arthroscopy (hip or knee).
Inclusion Criteria: Persistent Post-Surgical Pain Patients
Inclusion Criteria: Asymptomatic controls
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PPSP subjects who have undergone hip (or knee) joint arthroplasty (i.e., open surgical procedure for joint replacement). * 6 month post-op scans * 12 month post-op scans * 18 month post-op scans
Drug: FDG radiotracer · Device: PET/MRI · Device: PET/CT imaging
PPSP subjects who have undergone hip (or knee) arthroscopy (i.e., less invasive joint surgical procedure involving scopes and lower profile surgical tools) \- 6 month post-op scans
Drug: FDG radiotracer · Device: PET/MRI
Asymptomatic subjects who have undergone total hip or total knee arthroplasty. \- single scan during one study visit (up to 3.5 hours)
Drug: FDG radiotracer · Device: PET/MRI
Asymptomatic subjects who have undergone hip or knee arthroscopy. \- single scan during one study visit (up to 3.5 hours)
Drug: FDG radiotracer · Device: PET/MRI
Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-\[18F\]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection. Dosage planned 0.14 mCi/kg/patient.
Also known as: fluorodeoxyglucose, 18F-Fluorodeoxyglucose
positron emission tomography and magnetic resonance imaging
positron emission tomography and computed tomography imaging
Change in SUVmax (chronic pain)
Time frame: baseline (6 months post-op), 12 months post-op, 18 months post-op
SUVmax (chronic pain vs healthy)
Time frame: baseline
Location of Pain Compared to Target-to-Background (TTB) or SUVmax
Time frame: baseline
Number of Participants Where Standard FDG dose was sufficient to detect region of pain (symptomatic groups)
The standard administered adult dose of FDG currently used in clinics is 0.14 mCi/kg/patient.
Time frame: baseline
Variation of the maximum ratio of SUV (SUVRmax) in asymptomatic controls vs symptomatic
Time frame: baseline
Variation of the maximum ratio of SUV (SUVRmax) in symptomatic participants
Time frame: baseline (6 months post-op), 12 months post-op, 18 months post-op
Radiology Review Scores
Radiologists will evaluate MRI and CT images from each exam, and assign 1 point to any abnormality detected in the following compartments: prosthesis itself, bone, joint space, joint capsule, muscle, subcutaneous fat, and skin, for a total of 7 possible points. Differences in scoring from MRI vs CT images will be further investigated with a t-test.
Time frame: up to 18 months post-op
Change in Pain Scores (chronic pain)
Pain will be evaluated on a scale of 0 (no pain) to 10 (worse possible pain).
Time frame: baseline (6 months post-op), 12 months post-op, 18 months post-op
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2028, 43 months after the start.
Of 20 observational studies under Nociceptive Pain, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 21. This study's planned 43 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →